Joseph C. Del Paggio
Thunder Bay, ON, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Drug approvals in crowded drug classes potentially reflect efficacy overestimates and false positivity: A portfolio analysis of immune checkpoint inhibitor trials.
Journal: Journal of clinical epidemiology
Published: September 03, 2025
Proportion of patients in phase 2 oncology trials receiving treatments that are ultimately approved.
Proportion of patients in phase 2 oncology trials receiving treatments that are ultimately approved.
Journal: Journal of the National Cancer Institute
Published: July 10, 2024
Probability of Regulatory Approval Over Time: A Cohort Study of Cancer Therapies.
Journal: JCO oncology practice
Published: December 18, 2023
Bypassing phase 2 in cancer drug development erodes the risk/benefit balance in phase 3 trials.
Journal: Journal of clinical epidemiology
Published: January 14, 2023
Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity.
Journal: Current oncology (Toronto, Ont.)
Published: December 20, 2021
Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity-Reply.
Journal: JAMA oncology
Published: August 26, 2021
Industry Funding of Oncology Randomised Controlled Trials: Implications for Design, Results and Interpretation.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: April 06, 2021
Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.
Journal: JAMA oncology
Published: March 25, 2021
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials.
Journal: Current oncology (Toronto, Ont.)
Published: March 03, 2021
Last Updated: 09/26/2026